TOMI Environmental Solutions, Inc. reports developments tied to disinfection and decontamination products built around SteraMist iHP and Binary Ionization Technology. Company news commonly covers biocidal regulatory approvals, SteraMist applications in healthcare, life sciences, food safety, commercial facilities, transportation and remediation settings, and product categories such as BIT Solution consumables, integrated systems, mobile equipment and iHP Corporate Service offerings.
Updates also include operating and financial results, customer and service activity, training and application protocols, shareholder voting matters, governance topics, capital-structure disclosures and material agreements. TOMI's recurring business themes include the installed base for SteraMist delivery systems, consumable BIT Solution demand, engineered decontamination systems and professional decontamination services.
TOMI Environmental Solutions (TOMZ) reported preliminary third-quarter 2026 revenue of $2.5 million, up 27% from the third quarter of 2025. Revenue rose 13% from the second quarter, marking four consecutive quarters of sequential growth. The company expects preliminary third-quarter gross margin to exceed the second-quarter level.
At September 30, year-to-date recognized revenue plus the full open order book totaled $9 million. Open orders reached $2.5 million, versus $2.2 million at the second-quarter close, with $1.7 million booked for the fourth quarter. Third-quarter-end revenue plus full backlog, compared with full-year 2025, rose 107% for Mobile Equipment, 77% for Services and 330% for integrated automated projects. TOMI projects full-year BIT Solution sales above 2025, expects fourth-quarter and continued profitability, and views its $12 million 2026 revenue target as conditional. It continues evaluating potential merger candidates.
TOMI Environmental Solutions (NASDAQ: TOMZ) confirmed its readiness to support preparedness planning and front-line decontamination responses to outbreaks worldwide. The company said it can respond to requests with ready-to-deploy SteraMist systems, on-site decontamination services and its global partner network.
TOMI is monitoring reports of a suspected pneumonic plague case in Russia. Russian health authorities described the case as pneumonia of unknown origin; its cause has not been officially confirmed.
TOMI Environmental Solutions (NASDAQ: TOMZ) announced expansion in India's pharmaceutical sector after partner STS Technocrat signed a SteraMist customer.
The new customer is an unnamed pharmaceutical company. STS Technocrat distributes SteraMist and is working with TOMI to manufacture a fully integrated SteraMist iHP enclosure for decontamination. The partner is also pursuing several additional pharmaceutical opportunities. TOMI expects customer referrals to support adoption in India, following the pattern it has seen across U.S. life sciences.
TOMI Environmental Solutions (NASDAQ: TOMZ) announced that Project MEND has implemented SteraMist iHP to disinfect used medical equipment before reuse. The San Antonio nonprofit refurbishes and redistributes donated equipment to people with disabilities and limited financial resources. Its team uses the system on wheelchairs, walkers, hospital beds and other mobility aids.
Project MEND demonstrated SteraMist alongside refurbished equipment at the Houston Ability Expo earlier this year. TOMI said the organizations are continuing their awareness work through additional initiatives.
TOMI Environmental Solutions (TOMZ) announced modular integration concepts for its SteraMist iHP platform aimed at vehicle depots, drones and robotic systems. The company is exploring handheld application, whole-room fogging and integration onto robotic systems for automated decontamination. Its depot concepts cover rental-car operations and robotaxi fleets. These are potential applications under evaluation, not announced deployments.
TOMI Environmental Solutions (TOMZ) and Carbonium Core have mutually terminated their definitive Merger Agreement originally dated June 28, 2026. TOMI’s board approved the termination on September 20, 2026, after both parties concluded that proceeding with the business combination is no longer in the best strategic or financial interest of their stakeholders.
Under the Merger Agreement, each party will bear its own fees and expenses related to the proposed transaction. TOMI’s CEO, Dr. Halden Shane, stated that the company is benefiting from global adoption of its SteraMist solution, with high-margin, recurring revenue growth, a healthy pipeline and backlog, and that exiting the deal preserves its “clean capital structure” and allows renewed focus on improving operating results while pursuing other strategic partnerships.
TOMI Environmental Solutions (TOMZ) reported year-to-date 2026 SteraMist iHP Service and Support sales of approximately $1.7 million.
This represents about a 31% increase over full-year 2025 SteraMist iHP Service and Support revenue of roughly $1.3 million and exceeds full-year 2024 revenue, also about $1.3 million. The company highlights that this growth is increasing the recurring-revenue mix from contracted decontamination services and ongoing on-site support. In 2026, TOMI has completed multiple contracted SteraMist deployments, including four engagements each with Integra Pharma and Catalent, plus work for Cleveland Clinic and LFB USA, and four service visits to a Canadian university. TOMI also averages about four on-site support visits per month, including to CDC facilities, and plans to expand contracted service accounts and support through the rest of fiscal 2026.
TOMI Environmental Solutions (TOMZ) reports accelerating demand for its SteraMist iHP enclosure line, with about $2.3 million in enclosure purchase orders year-to-date 2026. This already exceeds by 44% the $1.6 million in comparable enclosure orders generated over the previous four years combined, reflecting faster customer adoption of the SteraMist Integration System (SIS) standardized platform.
Two recent retrofit orders, received within the past week, are expected to contribute revenue in the third and fourth quarters of 2026. TOMI also maintains a $3.2 million pipeline of Custom Engineered Systems and is co-developing an upgraded SteraBox iHP chamber with domestic and international partners for broader commercial and circular-economy applications.
TOMI Environmental Solutions (NASDAQ:TOMZ) reported that its Binary Ionization Technology BIT Solution has received formal approval in Ireland under the European Union’s Biocidal Products Regulation (BPR). This extends SteraMist authorizations to Ireland plus 10 other European markets including Austria, Italy, the Netherlands, Belgium, Denmark, Germany, Hungary, Spain, Great Britain and Northern Ireland.
The BPR approvals cover BIT Solution for both SteraMist room fogging and surface spraying equipment, for professional indoor use against bacteria, yeasts and mycobacteria across medical, healthcare, industrial, commercial, hospitality, institutional and tertiary sectors. According to TOMI, Ireland is a major life sciences and pharmaceutical hub where many of its existing and prospective contamination-control customers already operate.
TOMI Environmental Solutions (NASDAQ:TOMZ) reported Q2 2026 revenue of $2.25 million, up 118% year-over-year and 36% sequentially, driven mainly by capital equipment and Custom Engineered Systems. Gross profit rose 105% to $1.39 million, with gross margin at 61.7%. Operating loss narrowed 78% to $0.24 million, and net loss improved to $0.38 million ($0.05 per share). Q2 operating expenses fell 10% to $1.63 million.
The company reaffirmed its full-year 2026 revenue guidance of at least $12 million (113% YoY growth). Backlog was $2.2 million at June 30 (rising to $2.6 million post‑quarter), with a commercial pipeline of about $35 million and $8.6 million in advanced stages. Cash increased to $0.32 million, shareholders’ equity to $1.43 million, and working capital to $1.82 million.
TOMI signed a definitive merger agreement with Carbonium Core, under which Carbonium holders will receive 19.99% of TOMZ common stock at closing plus Series C preferred convertible into 90% of the combined company, contingent on shareholder approval and a required $10 million concurrent financing. The company also obtained unconditional EPA registration for SteraMist AgriMist, expanded EU/UK regulatory authorizations to 11 countries, and completed a 1‑for‑3 reverse stock split to regain Nasdaq minimum bid compliance.